QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Forecast, Price & News

$2.34
+0.08 (+3.54%)
(As of 09/21/2023 ET)
Compare
Today's Range
$1.98
▼
$2.35
50-Day Range
$2.26
▼
$2.90
52-Week Range
$1.95
▼
$4.92
Volume
20,336 shs
Average Volume
28,708 shs
Market Capitalization
$64.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Xilio Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
380.8% Upside
$11.25 Price Target
Short Interest
Healthy
0.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.81) to ($2.26) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

292nd out of 961 stocks

Pharmaceutical Preparations Industry

127th out of 448 stocks

See Top Rated MarketRank™ Stocks Here

XLO stock logo

About Xilio Therapeutics (NASDAQ:XLO) Stock

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO Price History

XLO Stock News Headlines

September 5, 2023 | markets.businessinsider.com
Xilio Therapeutics Appoints Katarina Luptakova As CMO
September 5, 2023 | finance.yahoo.com
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 21, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
September 5, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
August 18, 2023 | finance.yahoo.com
Q2 2023 Xilio Therapeutics Inc Earnings Call
August 14, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
August 3, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
July 20, 2023 | uk.finance.yahoo.com
XLO - Xilio Therapeutics, Inc.
September 21, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 25, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
May 12, 2023 | msn.com
Chardan Capital Reiterates Xilio Therapeutics (XLO) Buy Recommendation
May 10, 2023 | msn.com
Xilio Therapeutics GAAP EPS of -$0.83 beats by $0.06
May 9, 2023 | finanznachrichten.de
Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
May 9, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
April 3, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2023 | finance.yahoo.com
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023 | finance.yahoo.com
Xilio Therapeutics to Present at Upcoming Investor Conferences
February 16, 2023 | finance.yahoo.com
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
February 2, 2023 | finance.yahoo.com
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
January 26, 2023 | finance.yahoo.com
Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most
January 25, 2023 | seekingalpha.com
XLO Xilio Therapeutics, Inc.
January 25, 2023 | finance.yahoo.com
These 2 ‘Strong Buy’ Penny Stocks Are on Track for Massive Gains, Say Analysts
November 23, 2022 | finance.yahoo.com
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
November 9, 2022 | finance.yahoo.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
September 23, 2022 | finance.yahoo.com
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 6, 2022 | finance.yahoo.com
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
August 11, 2022 | seekingalpha.com
Xilio Therapeutics GAAP EPS of -$0.90
See More Headlines
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Company Calendar

Last Earnings
8/14/2023
Today
9/21/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XLO
CUSIP
N/A
CIK
1840233
Web
www.xiliotx.com
Phone
857-524-2466
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.25
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+380.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-88,220,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-87.74%
Return on Assets
-67.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.81
Quick Ratio
4.81

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.85 per share
Price / Book
0.61

Miscellaneous

Outstanding Shares
27,540,000
Free Float
26,273,000
Market Cap
$64.44 million
Optionable
Not Optionable
Beta
0.25
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Rene Russo BCPS (Age 48)
    Pharm.D, Pharm.D., CEO & Director
    Comp: $888.49k
  • Dr. Martin H. Huber M.D. (Age 62)
    Pres and Head of R&D
    Comp: $740.01k
  • Mr. Kevin M. Brennan (Age 53)
    Sr. VP of Fin. & Accounting and Director
  • Mr. Christopher Frankenfield
    Chief Operating Officer
  • Dr. Uli Bialucha Ph.D.
    Chief Scientific Officer
  • Julissa Viana
    VP of Corp. Communications
  • Ms. Stacey J. Davis
    Chief Bus. Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













XLO Stock - Frequently Asked Questions

Should I buy or sell Xilio Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares.
View XLO analyst ratings or view top-rated stocks.

What is Xilio Therapeutics' stock price forecast for 2023?

3 brokers have issued twelve-month price objectives for Xilio Therapeutics' shares. Their XLO share price forecasts range from $7.00 to $15.00. On average, they anticipate the company's share price to reach $11.25 in the next year. This suggests a possible upside of 380.8% from the stock's current price.
View analysts price targets for XLO or view top-rated stocks among Wall Street analysts.

How have XLO shares performed in 2023?

Xilio Therapeutics' stock was trading at $2.69 at the start of the year. Since then, XLO shares have decreased by 13.0% and is now trading at $2.34.
View the best growth stocks for 2023 here.

When is Xilio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our XLO earnings forecast.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its earnings results on Monday, August, 14th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.14.

When did Xilio Therapeutics IPO?

(XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

What is Xilio Therapeutics' stock symbol?

Xilio Therapeutics trades on the NASDAQ under the ticker symbol "XLO."

Who are Xilio Therapeutics' major shareholders?

Xilio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.05%) and Charles Schwab Investment Management Inc. (0.04%). Insiders that own company stock include Bain Capital Life Sciences Inv and Rock Springs Capital Managemen.
View institutional ownership trends.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xilio Therapeutics' stock price today?

One share of XLO stock can currently be purchased for approximately $2.34.

How much money does Xilio Therapeutics make?

Xilio Therapeutics (NASDAQ:XLO) has a market capitalization of $64.44 million. The company earns $-88,220,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis.

How can I contact Xilio Therapeutics?

The official website for the company is www.xiliotx.com. The company can be reached via phone at 857-524-2466 or via email at monique@thrustsc.com.

This page (NASDAQ:XLO) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -